---
title: Your July Monthly Beat
---

GALACTIC-HF shows that investigational agent omecamtiv mecarbil..

| View in browser JULY   Industry Updates JAMA Results of STEP trials with semaglutide 2.4mg for obesity management has experts excited about its potential   New England Journal of Medicine Investigational GLP-1 RA efpeglenatide reduces risk for CV events in patients with type 2 diabetes   ADA Diabetes Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions   ADA Diabetes Early Use of Sotagliflozin Provides Benefits for People With Type 2 Diabetes With Chronic Kidney Disease or Heart Failure   Endocrine Practice New AACE guideline for diabetes technology released   American College of Cardiology Registry Identifies Key Predictors of Major AFib Events in HCM     CMHC at the 2021 American Diabetes Association Scientific   CMHC Faculty Discussion Lipid Management in Very High-Risk Patients Post-MI: Applying Real World Evidence to Improve Outcomes - Expert Perspectives Watch Now   Featured Recipe   Spring 2021 On-Demand   Best Blog Read More           Cardiometabolic Health Congress, 1801 North Military, Suite 200, Boca Raton, Florida 33431, United States, 877.571.4700 Unsubscribe Manage preferences |
| --- |